Genomic DNA loci of Angiopoietin-like protein 3, Angiotensinogen, Lipoprotein(a), and Low-density lipoprotein receptor (ANGPTL3, AGT, LPA, and LDLR)

The genomic DNA loci for ANGPTL3, AGT, LPA, and LDLR represent a cluster of high-value therapeutic targets for cardiovascular and metabolic health (UniProt P59817, P01019, P08519, P01130). ANGPTL3 (Angiopoietin-like protein 3) regulates circulating triglycerides and LDL-C by inhibiting lipase enzymes, while LPA encodes Lipoprotein(a), a genetically determined risk factor for atherosclerosis (Musunuru et al., 2010, NEJM; Tsimikas, 2017, JACC). AGT (Angiotensinogen) serves as the sole precursor for angiotensin peptides, and its genetic suppression offers a novel approach to treating refractory hypertension (Desai et al., 2023, NEJM). The LDLR (Low-density lipoprotein receptor) locus is critical for hepatic cholesterol clearance, with therapeutic strategies focusing on maintaining or enhancing its expression to combat hypercholesterolemia (Brown & Goldstein, 1986, Science). These targets are increasingly addressed using genetic medicines, including siRNA, antisense oligonucleotides, and CRISPR-based gene editing technologies like base editing (Verve Therapeutics, 2024). By modulating these loci at the DNA or mRNA level, these therapies aim to provide durable, long-term reduction in cardiovascular events, potentially replacing the need for chronic daily medication.

Other names

Cardiovascular risk gene clusterLipid and blood pressure regulatory lociANGPTL3/AGT/LPA/LDLR genomic targets

Modulation of protein expression via gene editing (CRISPR/Base editing), RNA interference (siRNA), or antisense oligonucleotides (ASO) targeting specific genomic or transcriptomic sequences.